EUVIMEDEUVIMED entdecken
Crossref

Outcome of accelerated corneal cross-linking with 0.25% riboflavin in progressive keratoconus patients

CyuanYi Yeh, KuanI Huang, KaiTing Katy Liang, ChaoChien Hu, ShengFu Cheng

International Ophthalmology · 18.03.2026 · 46 (1)

DOI: 10.1007/s10792-026-04041-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Ophthalmology, online erschienen am 18.03.2026. Verfasst von CyuanYi Yeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen Chang Road, Taipei, Taiwan. Hauptthemen laut MEDLINE: Riboflavin, Keratoconus, Corneal Cross-Linking, Cornea. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: To present the one-year outcomes of accelerated corneal collagen cross-linking (CXL) with 0.25% riboflavin in the management of progressive keratoconus in the East Asian population. METHODS: A retrospective analysis was performed on twenty-four patients (32 eyes) diagnosed with progressive keratoconus treated in Taiwan. Exclusion criteria included corneas with a stromal thickness of less than 400 μm. A 15-min soak with 0.25% riboflavin was followed by UVA light exposure at 18 mW/cm2 for 5 min, achieving a total energy of 5.4 J/cm2. Corrected distance visual acuity, corneal topography, subjective refraction, endothelial cell density, corneal thickness were evaluated at baseline, 1, 3, 6, and 12 months postoperatively. The primary efficacy criterion was the changes in maximum keratometry (Kmax) at the 12-month follow-up. RESULTS: The mean Kmax decreased from 61.74 ± 9.9 to 60.05 ± 9.1 D at one-year follow-up (P = 0.002). Central corneal pachymetry decreased significantly from 464.16 ± 28.6 to 442.73 ± 87.6 μm (P < 0.001) at one year. The mean demarcation line depth was 375.91 ± 53.4 μm at one-month follow-up. Mean corrected distance visual acuity, manifest refraction and endothelial cell density remained unchanged. CONCLUSIONS: Our findings demonstrate the safety and efficacy of accelerated CXL with 0.25% riboflavin for progressive keratoconus, providing an effective option in clinical management. TRIAL REGISTRATION: This study retrospectively registered and approved by the Institutional Review Board (IRB) of the Shin Kong Wu Ho-Su Memorial Hospital. (IRB number: 20240403R).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RiboflavinKeratoconusCorneal Cross-LinkingCorneaHumansRetrospective StudiesFemalePhotosensitizing AgentsMaleAdultVisual AcuityCorneal TopographyFollow-Up StudiesYoung AdultTreatment OutcomeUltraviolet RaysCollagenRefraction, OcularAdolescentCorneal StromaDisease ProgressionCorneal Pachymetry

Stichwörter der Autor:innen

0.25% riboflavinCXLKeratoconus

Substanzen

RiboflavinPhotosensitizing AgentsCollagen

Autor:innen und Institutionen

  • Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen Chang Road, Taipei, Taiwan.
  • Department of Family Medicine, Tuen Mun Hospital, Hong Kong, China.
  • School of Medicine, Fu Jen Catholic University, New Taipei City, 242062, Taiwan.
  • Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen Chang Road, Taipei, Taiwan. paulyeh0525@gmail.com.
  • School of Medicine, Fu Jen Catholic University, New Taipei City, 242062, Taiwan. paulyeh0525@gmail.com.

Zitieren

APA

Yeh, C., Huang, K., Liang, K. K., Hu, C., & Cheng, S. (2026). Outcome of accelerated corneal cross-linking with 0.25% riboflavin in progressive keratoconus patients. International Ophthalmology, 46(1). https://doi.org/10.1007/s10792-026-04041-7

Vancouver

Yeh C, Huang K, Liang KK, Hu C, Cheng S. Outcome of accelerated corneal cross-linking with 0.25% riboflavin in progressive keratoconus patients. International Ophthalmology. 2026;46(1). doi:10.1007/s10792-026-04041-7

BibTeX
@article{Yeh2026,
  author = {Yeh, CyuanYi and Huang, KuanI and Liang, KaiTing Katy and Hu, ChaoChien and Cheng, ShengFu},
  title = {Outcome of accelerated corneal cross-linking with 0.25% riboflavin in progressive keratoconus patients},
  journal = {International Ophthalmology},
  year = {2026},
  volume = {46},
  number = {1},
  doi = {10.1007/s10792-026-04041-7}
}
Kostenlos starten →